GRAIL is pursuing commercialization and expansion of its Galleri test into Asian markets, including a collaboration in South Korea.
1 report, 1 independent
Updated Aug 5
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
GRAIL is pursuing commercialization and expansion of its Galleri test into Asian markets, including a collaboration in South Korea.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
GRAIL
American biotechnology and pharmaceutical company
-
Singapore
sovereign island country and city-state in maritime Southeast Asia
Related events
- A fund is investing in Asian markets, specifically mentioning companies like Samsung Electronics.
- Korean companies are key players in global tech supply chains, leveraging financial hubs like Singapore for market access.
- An unnamed entity announced on July 17th that it is expanding its operations into international markets, specifically targeting Singapore and Japan.
- Yili Group is establishing a global HQ in Singapore to expand its cognac market across Asia.